SCHEMBL411199

SCHEMBL411199

Cc1c(C)n(CC(CNc2ccccc2)OC(=O)C(=O)OC(CNc2ccccc2)Cn2c(C)c(C)c3ccccc32)c2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.68
KDM4E B2RXH2 9/20 0.68
MAPT P10636 4/20 0.68
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
TDP1 Q9NUW8 2/20 0.56
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
DNM1 Q05193 2/20 0.48
ALOX15 P16050 2/20 0.45
POLB P06746 1/20 0.45
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL411198 0.81 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL10257256 0.80 ALDH1A1 (0.90) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL410782 0.73 ALDH1A1 (0.78) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL409536 0.73 MAPT (0.80) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL410551 0.72 KDM4E (0.66) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL411693 0.72 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL411197 0.71 ALDH1A1 (0.75) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL18862013 0.70 ALDH1A1 (0.78) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL11608070 0.68 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL15570508 0.68 KDM4E (0.61) ALDH1A1KDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
US-20160206594-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-21 US claimed
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-10-15 US claimed
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 EP claimed
US-20150057301-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-26 US claimed
US-20140343018-A1 Anti-depression Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2014-11-20 US claimed
WO-2014031125-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-02-27 WO claimed
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP claimed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US claimed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BDNF, GAP43, DCX ALDH1A1 743/4885KDM4E 3126/4885MAPT 578/4885
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX ALDH1A1 1280/4885KDM4E 4210/4885MAPT 136/4885
US-20160206594-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF ALDH1A1 1654/4885KDM4E 2426/4885MAPT 559/4885
US-20150057301-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF ALDH1A1 1637/4885KDM4E 2423/4885MAPT 620/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX ALDH1A1 1280/4885KDM4E 4210/4885MAPT 136/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF ALDH1A1 1654/4885KDM4E 2426/4885MAPT 559/4885
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF ALDH1A1 1654/4885KDM4E 2426/4885MAPT 559/4885
US-20140343018-A1 Anti-depression Compounds BDNF, DCX, GAP43 ALDH1A1 1343/4885KDM4E 3990/4885MAPT 142/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX ALDH1A1 1280/4885KDM4E 4210/4885MAPT 136/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF ALDH1A1 1655/4885KDM4E 2509/4885MAPT 571/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF ALDH1A1 1654/4885KDM4E 2426/4885MAPT 559/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 ALDH1A1 1343/4885KDM4E 3990/4885MAPT 142/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 ALDH1A1 1343/4885KDM4E 3990/4885MAPT 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.